PreComb unveils plans to bring functional cancer profiling into clinical settings EU wide

Scientist in a lab coat using a microscope to conduct research, focusing on healthcare improvements.

Pioneering biotech company, PreComb, has unveiled revolutionary plans to bring functional cancer profiling into clinical settings EU wide.

Established in 2018 by three accomplished serial scientific entrepreneurs, PreComb is underpinned by its core mission is to accelerate oncology drug development by creating predictive, physiologically relevant tumour models and workflow technologies that mirror human biology more closely than traditional 2D or simple in vivo models.

Now entering its Series B funding round, the advanced biotech company is in the process of building a fully automated, on-site platform to test drug response on patient-derived 3D micro tumours.

By bringing high-throughput functional profiling into clinical environments, the technology aims to let institutions routinely test curated portfolios of cancer drugs and combinations — supporting pharma R&D and, pending regulatory approvals, helping to drive effective clinical decision-making.

This follows the success of its collaboration with University Hospital of Zurich, where both parties are working together to explore the potential of the LiveBank platform for pan-cancer drug discovery and development. This includes leveraging real-time patient-derived 3D cancer cell models to identify and profile novel therapeutic strategies across a broad range of tumour types.

 

Jens Kelm, Co-Founder and CSO of PreComb explained:

“With more than 100 chemotherapy drugs and 300 anti-cancer treatments approved by the FDA alone, patients are all-too-often faced with the prospect of trialling multiple options before finding a drug which effectively stabilises or shrinks their specific tumour.

At PreComb, our core goal is to reduce cancer-related deaths worldwide by making functional cancer profiling more accessible to patients through the development of our revolutionary 3DTwin® technology. In developing this advanced and automated solution – and in bringing it into community care settings – we are confident we can revolutionise cancer treatment and improve patient outcomes on a global scale.”

For more information, visit: https://www.precomb.com

About Editor 4283 Articles
Lisa Baker is the Editor of International Business News. As the Owner of Need to See IT Publishing, Lisa is an experienced business and technology journalist and publisher.